- Home
- CLGN vs BOLD Comparison
CLGN vs BOLD Comparison
Compare CLGN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- BOLD
- Stock Information
- Founded
- CLGN 2004
- BOLD 2018
- Country
- CLGN Israel
- BOLD United States
- Employees
- CLGN N/A
- BOLD N/A
- Industry
- CLGN Industrial Specialties
- BOLD
- Sector
- CLGN Health Care
- BOLD
- Exchange
- CLGN Nasdaq
- BOLD Nasdaq
- Market Cap
- CLGN 37.4M
- BOLD 30.3M
- IPO Year
- CLGN N/A
- BOLD 2024
- Fundamental
- Price
- CLGN $1.82
- BOLD $1.44
- Analyst Decision
- CLGN Strong Buy
- BOLD Hold
- Analyst Count
- CLGN 2
- BOLD 1
- Target Price
- CLGN $12.50
- BOLD N/A
- AVG Volume (30 Days)
- CLGN 12.7K
- BOLD 62.6K
- Earning Date
- CLGN 05-28-2025
- BOLD 05-09-2025
- Dividend Yield
- CLGN N/A
- BOLD N/A
- EPS Growth
- CLGN N/A
- BOLD N/A
- EPS
- CLGN N/A
- BOLD N/A
- Revenue
- CLGN $515,000.00
- BOLD N/A
- Revenue This Year
- CLGN $2,177.67
- BOLD N/A
- Revenue Next Year
- CLGN $56.52
- BOLD N/A
- P/E Ratio
- CLGN N/A
- BOLD N/A
- Revenue Growth
- CLGN N/A
- BOLD N/A
- 52 Week Low
- CLGN $1.82
- BOLD $1.06
- 52 Week High
- CLGN $6.75
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- CLGN 23.18
- BOLD N/A
- Support Level
- CLGN $2.00
- BOLD N/A
- Resistance Level
- CLGN $2.40
- BOLD N/A
- Average True Range (ATR)
- CLGN 0.21
- BOLD 0.00
- MACD
- CLGN -0.01
- BOLD 0.00
- Stochastic Oscillator
- CLGN 3.59
- BOLD 0.00
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.